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Edited by Varda RotterAbstract We previously reported that inhibition of SVH-B, a
speciﬁc splicing variant of SVH, results in apoptotic cell death.
In this study, we reveal that this apoptosis may be dependent
on the presence of p53. Co-immunoprecipitation and GST pull-
down assays have demonstrated that SVH-B directly interacts
with p53. In both BEL-7404 cells and p53-null Saos-2 cells trans-
fected with a temperature-sensitive mutant of p53, V143A,
ectopically expressed SVH-B suppresses the transcriptional
activity of p53, and suppression of SVH by RNA interference in-
creases the transcriptional activity of p53. Our results suggested
the function of SVH-B in accelerating growth and inhibition of
apoptosis is related to its inhibitory binding to p53.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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regulation1. Introduction
Speciﬁc splicing variant involved in hepatocarcinogenesis
(SVH) is closely related to the Armadillo proteins lost in epi-
thelial cancers on chromosome X (ALEX) family, which con-
tained at least three members: ALEX1, ALEX2, and ALEX3.
These genes composed of only one single exon, are closely
localized on chromosome Xq21.33–q22.2 [1]. However, SVH
gene is localized on chromosome 7q11.22 and composed of se-
ven exons. SVH is expressed in most human adult tissues.
There are four variants of SVH, namely SVH-A, B, C and
D, resulted from alternative splicing in the coding region of
the SVH transcript. These four variants share the same N-
and C-terminus, and all consist of a transmembrane domain
and a single armadillo repeat. However, only the B variant
of SVH (SVH-B) causes an accelerated-rate growth and con-
fers tumorigenicity to non-malignant hepatocyte in nude mice,Abbreviations: RNAi, RNA interference; TAD, transactivation
domain; DBD, DNA-binding domain; CTD, C-terminus domain
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doi:10.1016/j.febslet.2007.09.025and suppression of SVH-B in hepatoma cells line BEL-7404 re-
sults in apoptotic cell death [2].
p53, a tumor suppressor protein, plays a central role in cel-
lular processes such as growth arrest [3–5], DNA repair [5–8],
and apoptosis [9–12]. The human p53 gene encodes a 393-ami-
no acid protein and contains an N-terminus transactivation
domain (TAD, amino acids 1–73), a sequence-speciﬁc DNA-
binding domain (DBD, amino acids 100–293), and a C-termi-
nus domain (CTD, amino acids 293–393) [13–15]. A number of
regulators binding to p53 have been observed, and play vari-
ous roles in p53 transactivation. For example, TAFII31 binds
to the N-terminus of p53 and inhibits its activated transcrip-
tion [16]; 53BP1 and 53BP2 bind to the central domain of
p53 and enhance its mediated transcriptional activation [17];
p300 interacts with the C-terminus of p53 and stimulates its se-
quence-speciﬁc DNA binding [18].
In this study, we have demonstrated that SVH-B interacts di-
rectly with the DNA-binding domain of p53 and suppresses the
transcriptional activity of p53. The results shed light on the
molecular mechanism of growth control related to SVH-B gene.2. Materials and methods
2.1. Cell culture and transfection
BEL-7404 was purchased from Type Culture Collection of Chinese
Academy of Sciences, Shanghai. HEK-293T and Saos-2 were pur-
chased from ATCC. These cells and their derivatives, 7RS, 7RP-1,
and 7RP-2 cells [19], were maintained in Dulbecoo’s modiﬁed Eagle’s
medium (Gibco) containing 10% fetal bovine serum, 100 lg/ml strepto-
mycin sulfate, and 100 lg/ml penicillin at 37 C in 5% CO2. Transient
transfections were performed using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol.
2.2. Plasmid construction
Full-length human SVH-A, B, C, D, and p53 were cloned into
pcDNA3.1A (Invitrogen) and N-Flag-pcDNA3 (kindly provided by
Dr. Gang Pei) vectors, respectively. The mutant V143A of p53 was con-
structed by point-mutation of Flag-p53 using Quick-Change II XL site-
directed mutagenesis kit (Stratagene). Full-length human p53 and its
deletion mutants were cloned into pGEX-2 T (Amersham Biosciences).
2.3. Western blot
According to our previous protocol [2], the samples were loaded on
SDS–PAGE, transferred, probed with antibodies, and visualized with
enhanced chemiluminescence. Antibodies against SVH, myc-tag, p53,
GST (HanMan), a-tubulin (Zymed Laboratories), Flag, Flag-HRP
(Sigma–Aldrich), and p53-HRP (R&D Systems) were used.
2.4. In vivo co-immunoprecipitation
Co-transfected or non-transfected HEK-293T cells were lysed for 1 h
at 4 C in immunoprecipitation (IP) buﬀer (10 mM Tris–HCl, pH 7.4,blished by Elsevier B.V. All rights reserved.
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NP-40, 0.2 mM Na3VO3, and 0.2 mM PMSF). Cell extracts were incu-
bated with 2 lg/ml of mouse anti-myc, anti-SVH or IgG (HanMan)
overnight at 4 C. Immunocomplexes were isolated by incubation 2 h
at 4 C with protein A agarose (Invitrogen). Then, the immunoprecip-
itated samples were washed extensively with IP buﬀer. Western blot
was performed with the corresponding mouse anti-Flag-HRP or
anti-p53-HRP antibody.
2.5. Apoptosis assay
For measuring the cell apoptosis, cells were transfected with SVH-
RNAi and GFP-RNAi plasmids for 48 h, Annexin-V-FLUOS (Roche)
staining were performed according to the manufacturer’s protocol and
analyzed by ﬂow cytometry (Becton Dickinson).
2.6. In vitro GST pull-down
HEK-293T cells transfected with Flag-tagged SVH-B were lysed for
1 h at 4 C in IP buﬀer, and cell extracts were incubated with anti-Flag
(M2)-agarose beads (Sigma–Aldrich). Beads were washed with IP buf-
fer, and then eluted with the same buﬀer containing 0.2 mg/ml FLAG
peptide (Sigma–Aldrich). Bacteria expressed proteins of p53 and its
mutants were induced by 0.1 mM IPTG at 30 C for 2 h and puriﬁed
using glutathione agarose beads (BD Biosciences Pharmingen). SVH-
B-Flag, and p53, its mutants, or GST alone were each mixed and incu-
bated for 2 h at 4 C. The beads were separated by a brief centrifuga-
tion, washed with buﬀer 1 (50 mM Tris–HCl, pH 8.0, 150 mM NaCl,
0.1% NP-40, and 0.2 mM PMSF). Western blot was performed with
the corresponding mouse anti-Flag and anti-GST antibody.
2.7. Quantitative real-time RT-PCR assay
Total RNA extraction and reverse transcription were performed as
described previously [2]. To measure mRNA level of p21, a real-time
PCR assay was performed on a DNA Engine Opticon 2 (MJ Research)
using the DyNAmo SYBR Green qPCR kit (FINNZYMES). Human
p21 RT-PCR forward primer was CTGCCCAAGCTCTACCTTCC,
and its RT-PCR reverse primer was TGGAGAAGAT-
CAGCCGGCG. Human GAPDH RT-PCR forward primer was
GGGGAGCCAAAAGGGTCATCATCT, and its RT-PCR reverse
primer was GAGGGGCCATCCACAGTCTTCT. A threshold cycle
value for each mRNA was determined using the Opticon Monitor soft-
ware (version 2.02). All data were normalized to the GAPDH mRNA
level and expressed as mRNA relative change.
2.8. RNA interference
Plasmids encoding shRNAs directed against human SVH was con-
structed by cloning oligonucleotides targeting nucleotides 1056–1074
(GACCTGTTCCAGGTGTTAC) of SVH sequence (NM_031905),
in pSuper.retro.puro (OligoEngine), as previously described [20]. Oli-
gonucleotides targeting green ﬂuorescent protein (GFP) (GAACGG-
CATCAAGGTGAAC) was used as a control.
2.9. p53-mediated reporter assay
WWP-Luc, a p53-responsive luciferase reporter plasmid containing
CDKN1A (p21) promoter [3], was kindly provided by Dr. Bert Vogel-
stein. To measure p53 transcription activity, BEL-7404 cells were co-
transfected with WWP-Luc, pRL-TK (Promega), Flag-p53 and
SVH-B, pcDNA3.1A, SVH-RNAi or GFP-RNAi individually and
maintained for 48 h. The luciferase activity in cell lysates was measured
by a Dual-Luciferase Reporter Assay System (Promega) following the
manufacturer’s protocol.3. Results and discussion
3.1. SVH-B is the predominant SVH protein in BEL-7404 cells
Using an anti-SVH monoclonal antibody, overexpressed
Flag-tagged SVH-A, B, C, and D proteins were successfully
detected both in immunoblotting and immunoprecipitation as-
say (Figs. 1A and B). However, endogenous SVH proteins
from BEL-7404 cells could not be detected by Western blot
probably due to their low expression level (data not shown).Then the endogenous SVH proteins in BEL-7404 (Fig. 1C)
and HeLa cells (data not shown) were immunoprecipitated
and enriched using this antibody. The precipitated proteins
were validated by mass spectrometry. Together with the molec-
ular weight information, it showed that SVH-B protein was the
predominant format in both cell lines tested (Fig. 1C and data
not shown).3.2. RNAi suppression of SVH induces apoptosis in a p53-
dependent manner
We previously reported that speciﬁcally suppression of
SVH-B by antisense oligonucleotides treatment could induce
apoptosis in BEL-7404 cells [2]. It was well known that tumor
suppressor p53 plays a pivotal role in apoptosis [9–12]. So, we
investigate whether SVH-B inhibition induced apoptosis is
p53-dependent. Because BEL-7404 cells have wild type p53
expression, we generated the p53-RNAi stably transfected
BEL-7404 cells to completely ablate p53 [19]. RNAi ablation
of SVH was also conﬁrmed in BEL-7404 and Saos-2 cells
transfected with Flag-tagged SVH-B gene plasmid (Fig. 2A).
Then, SVH-RNAi or GFP-RNAi plasmid as control was
transfected into BEL-7404 cells with wild type p53 [parental
(Par) or 7RS cells] and p53-null (7RP-1 or 7RP-2 cells), respec-
tively. It showed that SVH-RNAi treatment increased apopto-
sis incidence in the parental BEL-7404 cells (from 12.01% to
17.74%) and control cell line 7RS (from 14.2% to 19.88%).
However, in the p53-null BEL-7404 cells, there was no signif-
icant change (Fig. 2B). The above results indicated that p53 is
involved in apoptosis induced by RNAi ablation of SVH.3.3. SVH-B interacts with p53 both in vitro and in vivo
Since SVH-B induced apoptosis is p53-dependent, we per-
formed both co-immunoprecipitation (Co-IP) and GST pull-
down assays to study whether SVH-B could interact with
p53 directly. In HEK-293T cells, Flag-tagged p53 plasmid
was co-transfected with myc-tagged SVH-B plasmid. Using
an anti-myc antibody, exogenous Flag-tagged p53 protein
was co-immunoprecipitated with exogenous myc-tagged
SVH-B protein (Fig. 3A). We also applied endogenous Co-
IP assay in HEK-293T cells. As Fig. 3B shown, after incuba-
tion of SVH antibody, endogenous p53 protein was co-immu-
noprecipitated with endogenous SVH protein. It suggested
that SVH protein could interact with p53 protein in vivo.
The interaction domain of p53 protein with SVH protein
was detected by in vitro GST pull-down assay. Series deletion
of p53 gene were constructed to map the binding domain for
SVH protein, including Full length (1–393), Deletion 1 (1–
101, containing N-terminus transactivation domain), Deletion
2 (98–322, containing DNA-binding domain), and Deletion 3
(293–393, the C-terminus domain). It was shown in Fig. 3C
that only the formats of Full length and Deletion 2 of p53 pro-
tein could pull down the SVH-B protein and the Deletion 2
was more eﬃcient than the whole protein. It indicated that
the DNA-binding domain of p53 is indispensable for the inter-
action between SVH-B and p53 proteins and some domains
out of the DNA-binding domain might inhibit the interaction.
In non-stressed cells, p53 is continuously shuttling in and out
of the nucleus, and its subcellular distribution varies through-
out the cell cycle. Under stress conditions, p53 is accumulated
in the nucleus where it induces or inhibits the expression of
stress response genes [21]. We examined the subcellular locali-
Fig. 1. SVH-B is the predominant SVH protein in BEL-7404 cells. (A) Four exogenous SVH proteins were detected by Western blot using a SVH
monoclonal antibody. HEK-293T cells were transfected with Flag-tagged SVH-A, B, C, and D. Cells lysates were blotted with a SVH antibody.
Alpha-tubulin was shown as a loading control. (B) Conﬁrmation of SVH antibody’s speciﬁcity by immunoprecipitation. Exogenous Flag-tagged
SVH proteins were immunoprecipitated with the SVH antibody and were detected with anti-Flag antibody. IgG was shown as a loading control. (C)
SVH-B is the predominant endogenous format in BEL-7404 cells. Lysates from BEL-7404 cells were immunoprecipitated with the SVH antibody,
separated by SDS–PAGE and stained by Coomassie-blue solution. The major band was cut and puriﬁed for peptide sequencing by mass
spectrometry. The peptide sequences indicating SVH-B were presented.
Fig. 2. Apoptosis induced by suppression of SVH is p53-dependent. (A) SVH-RNAi inhibited expression of Flag-tagged SVH-B gene in BEL-7404
and Saos-2 cells. BEL-7404 and Saos-2 cells were co-transfected with Flag-tagged SVH-B and SVH-RNAi or control GFP-RNAi plasmids. The cell
lysates were blotted with anti-Flag antibody. Alpha-tubulin was shown as a loading control. (B) Eﬀect of SVH ablation on apoptosis incidence in
wildtype p53 (Par or 7RS cells) and p53-null (7RP-1 or 7RP-2 cells). Cells were transfected with SVH-RNAi or GFP-RNAi plasmids as indicated.
After 48 h, Annexin-V-FLUOS staining were performed and analyzed by ﬂow cytometry. Results shown represent three independent experiments.
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pressed SVH protein was allocated mostly in the endoplasmic
reticulum (ER) [2], but the endogenous SVH protein also local-
ized in mitochondria and cell nucleus (data not shown). In
addition, SVH has two predicted nuclear export signals
(NES) and it would be accumulated in the cell nucleus by
mutation of NES, although SVH-B could not change the sub-
cellular localization of p53 (data not shown). It suggested that
SVH-B mostly interacted with p53 in the cell nucleus and sup-pressed the transcriptional activity of p53 throughout its bind-
ing to the specially DNA element.
3.4. SVH-B inhibits the transactivation activity of p53
The DNA-binding domain in p53 protein is the most impor-
tant functional unit for p53 to recognize and bind to the ele-
ment of its speciﬁc downstream target gene [3–11]. Because
SVH-B interacts with the DNA-binding domain directly, it is
necessary to explore whether the binding of SVH-B could
Fig. 3. Direct interaction between SVH-B and p53. (A) Exogenous co-IP assay. HEK-293T cells were co-transfected with myc-tagged SVH-B and
Flag-tagged p53 plasmids and then subjected to immunoprecipitation with anti-myc antibody. Co-immunoprecipitated Flag-tagged p53 protein was
detected with anti-Flag-HRP antibody. (B) Endogenous co-IP assay. Cell lysates from HEK-293T cells were incubated with anti-SVH antibody or
mouse IgG, immunoprecipitated proteins were detected by anti-p53-HRP antibody. (C) Mapping the interaction region of p53 protein with SVH-B
protein. The puriﬁed Flag-tagged SVH-B protein was incubated with GST-fused p53 full length, or deletion mutants, or GST alone as indicated, and
then isolated using glutathione-agarose beads. Bound proteins were detected with anti-Flag antibody. Arrows indicate the expression of p53 deletion
mutants.
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is a well-known downstream target gene of p53 [3]. By overex-
pression of SVH-B in BEL-7404 cells, mRNA expression level
of p21 gene was reduced 45% (Fig. 4A). A p53-responsive
luciferase reporter plasmid under the control of p21 promoter
containing the p53-binding sites, WWP-Luc, was used. Over-
expression of SVH-B also made a 57% decrease of luciferase
activity in p21 reporter (Fig. 4B). The similar results were also
obtained in QSG-7701 and HEK293 cells (data not shown). In
addition, suppression of endogenous SVH-B using RNA inter-
ference in BEL-7404 cells, could enhance both p21 transcripts
expression level (Fig. 4C) and activity of p21 transcriptional
reporter (Fig. 4D).
To generate a temperature-inducible p53 transactiviation
system, p53-null Saos-2 cells were transfected with a tempera-
ture-sensitive mutant of p53, p53V143A, which can induce trans-
activation of downstream target gene at 32 C or below, but
usually loose the transactional activity at 37 C [22]. As shown
in Fig. 4E, p21 expression was induced to peak (sevenfolds
comparing to the baseline) after 12 h cultured at 32 C by
ectopically expressed p53V143A. With the presence of p53V143A
at 32 C, overexpression of SVH-B dramatically inhibited theexpression of p21 by 90% (Fig. 4F), whereas SVH-RNAi in-
creased the p21 expression by 2 folds comparing to the control
GFP-RNAi (Fig. 4G). Thus, in two diﬀerent cell lines with
endogenous wildtype p53 or inducible-p53, we demonstrated
that SVH-B inhibited the transcriptional activity of p53.
It is well known that the transcriptional activity plays a piv-
otal role in mediating the p53 response. A lot of proteins have
been shown to interact with and play roles in p53 transactiva-
tion. Some directly inhibit its transcriptional activity (such as
TAFII31) [16]; some indirectly enhance it (such as 53BP1
and 53BP2) [17]; some directly increase it (such as p300) [18];
others change the stability of p53 (such as MDM2 and
Hsp90) [23,24]. Here, we have also demonstrated that SVH-
B interacts directly with the DNA-binding domain of p53
and suppresses the transcriptional activity of p53. It could par-
tially explain the growth accelerating function of SVH-B and
its possible involvement in hepatocarcinogenesis [2].
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Fig. 4. SVH-B inhibits the transcriptional activity of p53 gene. (A,C) Eﬀects of the SVH-B over-expression (A) and suppression (C) on the p21-
mRNA expression in BEL-7404 cells. mRNA level of p21 gene was measured by quantitative real-time PCR, normalized mRNA level of GAPDH
housekeeping gene. Cells transfected with control plasmids (pcDNA3.1A or GFP-RNAi) was deﬁned as 1. (B,D) Eﬀects of the SVH-B
overexpression (B) and suppression (D) on the luciferase activity of p21 reporter in BEL-7404 cells. WWP-Luc and pTK-RL plasmids were co-
transfected as transfection eﬃciency control. Luciferase activity was measured after 48 h transfection. (E) Temperature induced p21 mRNA
expression in p53V143A transfected Saos-2 cells. Forty-eight hours after p53V143A transfection, Saos-2 cells were cultured at 32 C or 37 C for
indicated time. The p21-mRNA expressions were measured by quantitative real-time PCR. (F,G) Eﬀects of the SVH-B over-expression (F) and
suppression (G) on the p21-mRNA expression in p53V143A transfected Saos-2 cells. Saos-2 cells were co-transfected with p53V143A and indicated
plasmids for 48 h, and maintained at 32C for 12 h. The mRNA levels of p21 were measured by quantitative real-time PCR. Data are shown as
means ± S.D. of three independent experiments.
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